Anke M. Nijhuis
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Rethinking ovarian cancer III: the past decade and future directions.
Journal: Nature reviews. Cancer
Published: February 23, 2026
RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination.
Journal: Communications biology
Published: December 16, 2024
Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn's Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets.
Journal: Journal of Crohn's & colitis
Published: September 07, 2023
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Journal: Cell reports
Published: April 26, 2023
Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease.
Journal: Clinical science (London, England : 1979)
Published: October 01, 2021
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Journal: Nature communications
Published: November 03, 2020
RNA-binding motif protein 39 (RBM39): An emerging cancer target.
Journal: British journal of pharmacology
Published: August 10, 2020
Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells.
Journal: British journal of cancer
Published: June 10, 2019
Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition.
Journal: Journal of cellular and molecular medicine
Published: March 25, 2018
GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions.
Journal: Oncotarget
Published: March 29, 2017
Last Updated: 09/26/2026